NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults

Phase 1

Completed

Conditions: Healthy Adult Immune Responses to Vaccine

Interventions: Biological: VRC-EBOMVA079-00-VP (MVA-EbolaZ)
Biological: VRC-EBOADC069-00-VP (cAd3-EBO)

First Posted Date: 2015-04-06

Last Posted Date: 2019-04-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 140

Registration Number: NCT02408913

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
Hope Clinic - Emory Vaccine Ctr, Decatur, Georgia, United States
🇺🇸
University of Maryland, Baltimore, Baltimore, Maryland, United States

A Safety and Immune Response Study of 2 Experimental HIV Vaccines

Phase 1

Completed

Conditions: HIV Infection

Interventions: Biological: ALVAC-HIV
Biological: ALVAC-HIV (vCP2438) Placebo
Biological: Bivalent gp120/MF59® Placebo
Biological: Bivalent Subtype C gp120/MF59®

First Posted Date: 2015-03-31

Last Posted Date: 2021-11-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 252

Registration Number: NCT02404311

Locations: 🇿🇦
Isipingo CRS, Durban, KwaZulu-Natal, South Africa
🇿🇦
CAPRISA eThekwini CRS, Durban, KwaZulu-Natal, South Africa
🇿🇦
Aurum Institute for Health Research, Klerksdorp, South Africa

and more 2 locations

Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults

Phase 1

Completed

Conditions: Dengue

Interventions: Biological: rDEN1Δ30
Biological: Placebo
Biological: rDEN2Δ30-7169

First Posted Date: 2015-03-18

Last Posted Date: 2018-02-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 12

Registration Number: NCT02392325

Locations: 🇺🇸
Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland, United States

Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: ZMAPP

First Posted Date: 2015-03-17

Last Posted Date: 2019-12-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT02389192

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

Phase 4

Terminated

Conditions: Influenza
Influenza Immunisation

Interventions: Biological: Influenza Virus Vaccine Inactivated

First Posted Date: 2015-03-11

Last Posted Date: 2023-10-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT02385123

Locations: 🇺🇸
Emory University Hospital - W. Dean Warren General Clinical Research Center (GCRC), Atlanta, Georgia, United States

Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Volunteer Human Challenge Model

Phase 2

Completed

Conditions: H1N1 Influenza Healthy Volunteers

Interventions: Biological: Placebo
Biological: CR6261

First Posted Date: 2015-02-26

Last Posted Date: 2020-03-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 104

Registration Number: NCT02371668

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis

Phase 2

Completed

Conditions: Pulmonary Tuberculosis

Interventions: Drug: Treatment
Radiation: PET/CT Scan
Procedure: Sample Collection

First Posted Date: 2015-02-26

Last Posted Date: 2023-06-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 262

Registration Number: NCT02371681

Locations: 🇿🇦
Stellenbosch University, Faculty of Medicine and Health Sciences, Cape Town, South Africa
🇿🇦
TASK Applied Sciences, Cape Town, South Africa

Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection

Phase 1

Completed

Conditions: Ebola Virus Infection

Interventions: Other: A/Current Standard of Care Alone
Drug: B/Current Standard of Care Plus ZMapp

First Posted Date: 2015-02-16

Last Posted Date: 2019-06-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 72

Registration Number: NCT02363322

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇬🇳
CTE Forecariah, Forecariah, Guinea
🇸🇱
International Medical Corps (IMC) Lunsar, Port Loko, Sierra Leone

and more 8 locations

Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048

Phase 1

Completed

Conditions: HIV Infections

Interventions: Device: MK-2048A IVR
Device: Placebo IVR
Device: Vicriviroc (MK-4176) Intravaginal Ring (IVR)
Device: MK-2048 IVR

First Posted Date: 2015-02-05

Last Posted Date: 2021-10-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 48

Registration Number: NCT02356302

Locations: 🇺🇸
Alabama CRS, Birmingham, Alabama, United States
🇺🇸
University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States

Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

Phase 1

Completed

Conditions: Hemorrhagic Fever, Ebola

Interventions: Biological: cAd3-EBOZ
Biological: cAd3-EBO
Biological: MVA-EbolaZ

First Posted Date: 2015-02-03

Last Posted Date: 2017-12-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 90

Registration Number: NCT02354404

Locations: 🇺🇬
Makerere University Walter Reed Project, Kampala, Uganda

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy